GlassScriptPhysician profile
Jeremy Jones
NPI 1376839688
$5,448.91
in general payments reported to CMS, 2019-2025
26 companies · $221 in 2025
The $221 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,475 · 2020: $940 · 2021: $1,655 · 2022: $546 · 2023: $393 · 2024: $218 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $832.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $1,360.78 | 2019-2020 | |
| Medtronic, INC. | $1,282.60 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Boston Scientific Corporation | $819.53 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $371.18 | 2019-2021 | |
| Abbvie INC. | $370.83 | 2021-2025 | |
| Abbott Laboratories | $362.80 | 2019-2024 | Eterna |
| Relievant Medsystems, INC. | $164.02 | 2023 | Intracept |
| Si-Bone, INC. | $143.51 | 2021-2022 | |
| Allergan, INC. | $74.67 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $54.89 | 2020-2021 | |
| Depuy Synthes Sales INC. | $52.69 | 2021-2023 | Monovisc |
| Lilly USA, LLC | $48.06 | 2019-2023 | Emgality, Reyvow |
| Teva Pharmaceuticals USA, INC. | $43.95 | 2019 | |
| Pfizer INC. | $33.56 | 2019 | |
| Horizon Therapeutics Plc | $31.60 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $30.15 | 2019 | |
| Biodelivery Sciences International, INC. | $29.65 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $28.70 | 2021 | |
| Acacia Pharma INC | $24.55 | 2021 | |
| Averitas Pharma INC. | $22.54 | 2025 | Qutenza |
| Vertex Pharmaceuticals Incorporated | $20.47 | 2024 | |
| Redhill Biopharma INC. | $18.31 | 2020 | |
| Vertiflex, INC. | $16.71 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.10 | 2021 | |
| Nalu Medical, INC. | $15.76 | 2022 | |
| Pacira Therapeutics, INC. | $11.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.